Clin2
NCT06158139Possibly a fitRecruiting

Testing modified immune cells for pancreatic cancer

Pancreas CancerRelapseResistant Cancer

Part of Cancer, Digestive system, Hormones & metabolism clinical trials.

This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target a protein called B7-H3 found on pancreatic cancer cells. The goal is to see if this therapy can help shrink or control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
27 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be at least 18 years old.
  • You must have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer).
  • You must be able to do most daily activities (like walking, light chores) without help.
  • If you could become pregnant, you must agree to use two forms of effective birth control during the study.
  • You must be willing to sign a consent form and share your health information with the study team.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06479239Recruiting· Phase 1/Phase 2
Immune cell therapy for advanced pancreatic cancer

This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.

Charlottesville, Virginia
NCT06347068Recruiting· Phase 1
CAR-T cell therapy for triple-negative breast cancer

This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.

Chapel Hill, North Carolina
NCT07394205Not yet recruiting· Early Phase 1
CAR-T cell therapy for advanced stomach and pancreatic cancer

This trial tests a new type of immune cell therapy called CBG131 CAR-T cells for people with advanced stomach or pancreatic cancer that has stopped responding to standard treatments. The therapy targets a protein called CLDN18.2 on cancer cells, and the study aims to see if it can shrink tumors.

Wenzhou, Zhejiang
NCT07153289Not yet recruiting· Phase 1/Phase 2
CAR T cells targeting CD318 for pancreatic cancer

This trial tests a new kind of immune treatment called CAR T cells that target a protein (CD318) found on some pancreatic cancer cells. It's for people with advanced pancreatic cancer whose disease has worsened after standard treatment.

NCT06503497Recruiting· Early Phase 1
NK cell therapy for pancreatic cancer after standard treatment

This trial tests a new therapy using your own immune cells (NK cells) that are specially trained to find and attack cancer cells. It is for people with pancreatic cancer that has not responded to previous treatment.

Hangzhou, Zhejiang
NCT07425483Recruiting· Phase 1
CAR-NK cell therapy for advanced pancreatic cancer

This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.

Shanghai

Hear when a new Pancreas Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.